PUBLIC COMPANY
save$IRDOpus Genetics, Inc.
$IRD2.9200-4.26%Durham, NC, USupdated 11d ago
community read0 votes
pipeline
6
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
3Preclinical1Phase 21Phase 31Marketed
Marketed
phentolamine mesylate
Presbyopia
Adrenergic receptor alpha
Phase 3OPGx-LCA5
Leber Congenital Amaurosis (LCA)
Phase 2OPGx-BEST1
Macular Degeneration
PreclinicalOPGx-CNGB1
Retinitis Pigmentosa (Retinitis)
PreclinicalOPGx-RDH12
Leber Congenital Amaurosis (LCA)
PreclinicalOPGx-RHO
Retinitis Pigmentosa (Retinitis)
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
- phase2Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 20, 26grantBenton Susan · director24,367 sh
- Apr 20, 26grantRodgers Richard J · director24,367 sh
- Apr 20, 26grantAinsworth Sean · director24,367 sh
- Apr 20, 26grantBennett Jean · director24,367 sh
- Apr 20, 26grantMANUSO JAMES S J · director24,367 sh
- Apr 20, 26grantGraves Adrienne L · director24,367 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that